Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TAREK ELDAWY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1669416459
CMS profile
166338
Location
OVIEDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$8,167.00

256 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,640.06 241
Consulting Fee $1,420.00 1
Long term medical supply or device loan $999.96 12
Education $106.98 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $1,499.30 5
Novartis Pharmaceuticals Corporation $1,387.74 33
AstraZeneca Pharmaceuticals LP $614.10 23
PFIZER INC. $382.08 21
ADC THERAPEUTICS AMERICA, INC. $337.53 5
Janssen Biotech, Inc. $311.49 18
ABBVIE INC. $275.72 15
Merck Sharp & Dohme LLC $253.61 11
Daiichi Sankyo Inc. $224.94 11
PharmaEssentia USA Corporation $221.33 5
Celgene Corporation $210.50 9
SOBI, INC $177.04 4
GlaxoSmithKline, LLC. $158.01 5
Takeda Pharmaceuticals U.S.A., Inc. $156.45 5
GENZYME CORPORATION $131.57 6
Gilead Sciences, Inc. $127.00 6
SEAGEN INC. $99.99 1
Genentech USA, Inc. $96.74 4
Incyte Corporation $90.07 4
ARRAY BIOPHARMA INC $78.60 4
Kite Pharma, Inc. $76.38 3
Eisai Inc. $71.85 3
Astellas Pharma US Inc $69.35 4
Syndax Pharmaceuticals, Inc. $64.59 3
Dendreon Pharmaceuticals LLC $62.42 3
Karyopharm Therapeutics Inc. $61.39 3
Novocure Inc. $59.87 3
Bayer Healthcare Pharmaceuticals Inc. $58.88 3
EMD Serono, Inc. $58.58 3
Boehringer Ingelheim Pharmaceuticals, Inc. $53.16 2
Fennec Pharmaceuticals, Inc. $48.58 2
Alexion Pharmaceuticals, Inc. $43.50 2
JAZZ PHARMACEUTICALS INC. $42.44 2
BeOne Medicines USA, Inc. $41.56 2
Agios Pharmaceuticals, Inc. $41.46 2
Pharmacosmos Therapeutics Inc. $36.75 1
Immunocore Limited $31.74 1
Adaptive Biotechnologies Corporation $30.00 1
KYOWA KIRIN, INC. $29.12 1
Corcept Therapeutics $28.35 1
TerSera Therapeutics LLC $27.00 1
Amneal Pharmaceuticals LLC $26.31 1
Geron Corporation $23.39 1
Tempus AI, Inc $22.77 1
Deciphera Pharmaceuticals Inc. $22.26 1
Lilly USA, LLC $22.10 1
Blueprint Medicines Corporation $20.68 1
SERVIER PHARMACEUTICALS LLC $19.30 1
Regeneron Healthcare Solutions, Inc. $19.28 1
Menarini Silicon Biosystems, Inc. $18.59 1
Coherus Oncology, Inc. $18.50 1
Exelixis Inc. $17.98 1
RECORDATI_RARE_DISEASES_INC. $17.70 1
Amgen Inc. $16.90 1
Ipsen Biopharmaceuticals, Inc $15.73 1
SpringWorks Therapeutics, Inc. $14.73 1

Page 3 of 6; records 101–150 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TAREK ELDAWY

NPI 1669416459 · CMS profile ID 166338

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

OVIEDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669416459?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TAREK ELDAWY, NPI 1669416459, CMS profile ID 166338. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669416459?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). TAREK ELDAWY, NPI 1669416459, CMS profile ID 166338. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669416459?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
TAREK ELDAWY, NPI 1669416459, CMS profile ID 166338, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 256 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669416459?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

256 matching records · $8,167.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 256 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 256.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $10.9907/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197086295 CMS
Novartis Pharmaceuticals Corporation $83.3307/25/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200073026 CMS
AstraZeneca Pharmaceuticals LP $28.8407/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206158844 CMS
Celgene Corporation $2.4007/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184940459 CMS
Janssen Biotech, Inc. $17.4607/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175200434 CMS
GlaxoSmithKline, LLC. $16.0207/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191462346 CMS
Merck Sharp & Dohme LLC $17.6507/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238304917 CMS
PFIZER INC. $12.2507/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230202884 CMS
Incyte Corporation $21.6907/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226133119 CMS
ABBVIE INC. $15.1907/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201810419 CMS
Daiichi Sankyo Inc. $19.4407/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197090765 CMS
Geron Corporation $23.3907/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238888288 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.1007/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223917536 CMS
Novartis Pharmaceuticals Corporation $23.3607/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200073076 CMS
PFIZER INC. $11.5007/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230192329 CMS
PFIZER INC. $25.1907/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230283182 CMS
EMD Serono, Inc. $20.1907/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236905613 CMS
Celgene Corporation $31.8907/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184940469 CMS
Astellas Pharma US Inc $22.0206/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238804438 CMS
Exelixis Inc. $17.9806/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218806204 CMS
PharmaEssentia USA Corporation $27.7906/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246825682 CMS
ABBVIE INC. $28.4006/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201810417 CMS
ADC THERAPEUTICS AMERICA, INC. $145.3806/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246118986 CMS
ADC THERAPEUTICS AMERICA, INC. $121.0406/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246125292 CMS
Gilead Sciences, Inc. $19.1406/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234537387 CMS
Janssen Biotech, Inc. $17.6406/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175199653 CMS
Janssen Biotech, Inc. $5.4706/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175201371 CMS
TerSera Therapeutics LLC $27.0006/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244062705 CMS
ABBVIE INC. $6.0306/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201810415 CMS
Agios Pharmaceuticals, Inc. $15.5606/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253248185 CMS
PFIZER INC. $21.9006/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230261580 CMS
ADC THERAPEUTICS AMERICA, INC. $19.0306/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246112939 CMS
AstraZeneca Pharmaceuticals LP $25.7106/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206687557 CMS
Novartis Pharmaceuticals Corporation $83.3306/12/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200073024 CMS
Deciphera Pharmaceuticals Inc. $22.2606/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235958867 CMS
AstraZeneca Pharmaceuticals LP $24.4406/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206574488 CMS
PFIZER INC. $19.7006/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230282982 CMS
Eisai Inc. $27.1606/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244515598 CMS
Janssen Biotech, Inc. $20.6906/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175199359 CMS
JAZZ PHARMACEUTICALS INC. $22.4606/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234333257 CMS
Merck Sharp & Dohme LLC $24.4306/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238304925 CMS
PFIZER INC. $13.9805/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230192284 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.6205/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223893423 CMS
AstraZeneca Pharmaceuticals LP $34.7005/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206528772 CMS
Ipsen Biopharmaceuticals, Inc $15.7305/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208834040 CMS
ADC THERAPEUTICS AMERICA, INC. $32.7505/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246113230 CMS
Merck Sharp & Dohme LLC $17.0005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238180939 CMS
Novartis Pharmaceuticals Corporation $20.5805/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200073078 CMS
GlaxoSmithKline, LLC. $1.8305/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191662070 CMS
Incyte Corporation $20.9305/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226109363 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,516.48 34
PY2020 $3,148.16 4
PY2021 $295.42 9
PY2022 $4,843.18 44
PY2023 $7,802.24 93
PY2024 $8,653.13 253
PY2025 $8,167.00 256

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $16,750.00 3
PY2022 Principal investigator $32,722.02 9
PY2021 Principal investigator $14,349.53 7
PY2020 Principal investigator $29,488.30 7
PY2019 Principal investigator $191,044.85 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

3 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,000.00 09/12/2023 Non-covered Recipient Entity
STUDER FAMILY CHILDRENS HOSPITAL
A randomized double blind placebo controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer who received no prior hormonal therapy for advanced disease No dispute reported 06/30/2026 1017238707
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $500.00 06/07/2023 Covered Recipient Teaching Hospital
Ascension Sacred Heart Pensacola
Phase III Study Adj GEJ & Esoph (US EU) (mono) - A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal or Gastroesophageal Junction Cancer No dispute reported 06/30/2026 1027467115
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,250.00 04/20/2023 Covered Recipient Teaching Hospital
Ascension Sacred Heart Pensacola
PhIII Stage 3/4 Resectable Mel Adj Rela+Nivo vs Nivo - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [ No dispute reported 06/30/2026 1027479761